JNJ · Johnson & Johnson
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Research
our published analysis of this company
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Operational Sales non-GAAP | 5.7% | Q2 2026 | — |
|
|
|||
| Free Cash Flow non-GAAP | $8.7B | Q2 | — |
|
|
|||
| Operational Sales non-GAAP | 5.6% | Q2 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
JNJ
this stock
Johnson & Johnson
|
$658.89B | +29.2% | +6.0% | 31.8 | 1.1% |
|
LLY
ELI LILLY & Co
|
$1.21T | +15.8% | +44.7% | 43.0 | 1.0% |
|
ABBV
AbbVie Inc.
|
$462.68B | +14.6% | +8.6% | 74.0 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$375.50B | +41.5% | +1.3% | 121.8 | 1.1% |
|
NVS
Novartis AG
|
$304.70B | +13.3% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| JNJ | +2.0% | +3.1% | +7.6% | +4.3% | +29.2% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +4.0% | -0.2% | -3.6% | +2.2% | +17.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.